Strong partnerships and licensing agreements with leading scientists, academic centers of excellence, innovative biotech companies and high quality manufacturers are recognized as key to RESprotects development and success. The company has worked diligently to create successful and productive relationships.

Current Partnerships

RESprotect has strong scientific co-operations with the Universities of Dresden, Wien and Leipzig.

• Fraunhofer Institut für Toxikologie und Experimentelle Medizin (ITEM), Hannover/Germany
• Fraunhofer-Institut für Zelltherapie und Immunologie (IZI), Leipzig/Germany
• Institut für Tumorbiologie-Krebsforschung, Universität Wien/Austria
• Biotec/Department of Computing, Technical University Dresden/Germany  

RESprotect partnered with chemists of WITEGA/Berlin, Institut für Pharmazeutische Chemie Universität Leipzig and ERCOM/Budapest/Hungary to synthesize next generation drug candidates discovered and designed.

RESprotect partnered with Nycomed Linz, Austria for the synthesis and production of product candidates under GMP conditions.

RESprotect partnered with Pharbil, Göttingen for the production of RP101 tablets under GMP conditions.

RESprotect partnered with SciClone Pharmaceuticals, Inc., Foster City, California when it transferred the North American license for RP101 from Avantogen Inc., Los Angeles.

RESprotect partnered with Kwang Dong Pharmaceuticals, Inc., Seoul, South Korea, when out- licensed the RP101 rights for South Korea.

Future Partnerships

In addition to current partnerships RESprotect is seeking further partnerships and out-licensing opportunities.

Given the blockbuster potential of RP101 if effective in multiple large tumor settings, and in combination with many different cytotoxic drugs, RESprotect is looking to out-license the clinical development and commercial rights of RP101 in Europe, South America and Asia.

 RESprotect is also keen to explore worldwide partnerships to develop its exciting, novel early stage pre-clinical/Phase I pipeline products (RP525, RP656, RP7101 or RP885), focusing on specialized therapy combinations in treatment of selected cancer indications.